HBx基因缺失突变体（HBx-d382）对L02细胞增殖的影响及其相关机制探讨
|
摘要
目的：原发性肝细胞癌(Hepatocellular carcinoma, HCC)是来源于肝细胞的恶性肿瘤,是世界上最常见的恶性肿瘤之一。流行病学研究表明慢性乙型肝炎病毒感染和原发性肝癌的发生发展密切相关,几乎所有HBV (hepatitis B virus)相关的肝癌组织中可以检测到基因组整合的HBV DNA。在众多病毒基因组整合亚单位中HBx(Hepatitis B virus x gene)基因可以转录并翻译成相应HBx蛋白,其与肝癌的关系被广泛研究。我们前期研究发现在肝癌组织的基因组中广泛存在HBx基因的整合和突变,并筛选出2个缺失突变体HBx-d382(HBx基因nt382-400缺失突变)和HBx-d431,其中HBx-d382在肝癌组织中检出率较高,我们猜想HBx-d382可能与肝细胞癌密切相关,随后我们成功构建了HBx-d382真核表达载体pcDNA3.0/HBx-d382。本研究将建立稳定表达HBx基因缺失突变体(HBx-d382)的L02肝细胞株L02/HBx-d382,探讨HBx-d382对L02细胞增殖,G1期细胞周期调控及microRNA表达谱的影响。
方法：含HBx-d382的重组质粒(pcDNA3.0/HBx-d382)经过PCR(Polymerase chain reaction)扩增、双酶切及DNA测序鉴定后,通过脂质体转染和G418筛选获得稳定表达HBx-d382的L02肝细胞株,PCR鉴定L02细胞基因组中HBx-d382基因整合,RT-PCR(Reverse transcription polymerase chain reaction)和western blot鉴定其表达。通过MTT法,软琼脂克隆形成实验检测HBx-d382对L02细胞增殖及非锚定依赖生长能力的影响,用流式细胞仪检测其对细胞周期的影响；通过real-time定量PCR及western-blot鉴定转染HBx-d382后L02细胞cyclin D1,cylinG1,E2F1表达改变；通过microRNA芯片技术检测HBx-d382对L02细胞miRNA (microRNA)表达谱的影响。
结果：(1)经PCR、酶切及测序鉴定HBx-d382重组质粒构建正确。(2)稳定转染该质粒的L02细胞基因组存在HBx-d382整合,RT-PCR及Western-blot表明在RNA水平和蛋白水平存在HBx-d382表达。(3) MTT及软琼脂克隆形成实验结果表明稳定表达HBx-d382的L02细胞其增殖能力和非锚定生长能力增强,细胞周期检测证实转染HBx-d382的L02细胞S+G2期细胞比例升高。(4)real-time定量PCR结果表明与转染空质粒pcDNA3.0的L02细胞(L02/pcDNA3.0)相比L02/HBx-d382细胞cyclin D1, cylin G1, E2F1的mRNA表达明显增强(P<0.05);western-blot结果证实与102/pcDNA3.0细胞相比L02/HBx-d382细胞cyclin D1, cylin G1, E2F1蛋白表达明显增强(p<0.05) (5)microRNA芯片发现与L02/pcDNA3.0组细胞相比L02/HBx-d382组细胞mir-1,mir-338-3p, mir-551b, miR-455-3p, miR-200c表达下调,miR-501,miR-595, miR-1307, miR-1180, miR-497, miR-1246, miR-623表达上调。
结论：本研究成功的构建了HBx基因缺失突变体(HBx-d382)的真核表达模型,证实HBx-d382能增强L02细胞增殖及非锚定依赖生长能力。HBx-d382促使L02细胞打破G1期阻滞,进入S期,这种效应可能与其增强G1调控相关基因如cyclin D1, cylin G1, E2F1表达有关。HBx基因缺失突变体(HBx-d382)能影响L02肝细胞microRNA的表达谱,这为阐明HBx-d382致肝细胞恶性转化提供新的分子生物学机制。
Objective:Hepatocellular carcinoma (HCC) is a malignant tumor arising from hepatocytes; it is one of the most common malignancies worldwide. Epidemiological studies have showed that there is a strong relationship between the chronic hepatitis B virus infection and development of hepatocellular carcinoma, almost all of the HBV-associated HCCs harbor chromosomally integrated HBV DNA. In most integrated subviral HBV genomes, the HBx gene can be transcribed and translated into HBx protein, its significance in the hepatocarcinogenesis is be widely studied. our previous study has found that HBx gene integration and mutation occur frequently in HCC samples, and isolated two HBx deletion mutations naming HBx-d431 and HBx-d382(HBx gene nt 382-400 deletion),among which the HBx-d382 occurs more frequently in HCC samples, we guess it may be implicated in liver carcinogenesis, and then we have successfully constructed the eukaryotic expression vector for the expression of HBx-d382.In this study, we will establish a L02 cell line stably expressing HBx deletion mutation (HBx-d382) and further study the influence of HBx-d382 on cell proliferation,G1 cell cycle control and microRNA expression profile of L02 cells.
Methods:The recombinant plasmid encoding the HBx deletion mutation (pcDNA3.0/HBx-d382) was tested by PCR amplification、double digestion and DNA sequencing, and then introduced into L02 cells by liposome transfection. Positive clones were selected by G418. The genome integration of the HBx gene was test by PCR amplification, and the HBx expression was confirmed by reverse transcription PCR (RT-PCR) and western blot. Cell proliferation changes were measured by MTT assay and soft agar clone formation assay, and the cell cycles were tested by flow cytometry; the mRNA and protein expression of cyclin D1, cylin G1, E2F1 were detected by Real-time Quantitative PCR and Western blot respectively; microRNA expression profiles were analyzed by microRNA microarray.
Results:(1)The recombinant plasmid pcDNA3.0/HBx-d382 was successfully identified by PCR amplification、double digestion and DNA sequencing. (2)Positive clone that selected by G418 harbored chromosomally integrated HBx-d382; RT-PCR and Western blot confirmed the HBx expression at the mRNA and protein lever respectively.(3)This cell line showed enhanced proliferation and anchorage-independent growth ability when tested by MTT assay and soft agar clone formation assay; and the proportion of S and G2 phrase cells was increased simultaneously. (4)Real-time Quantitative PCR showed that the mRNA expression of cyclin D1, cylin G1, E2F1 were increased in L02/HBx-d382 cells compared with L02 cells transfected with the pcDNA3 empty plasmid(102/pcDNA3.0) (p<0.05); Western blot confirmed that the protein expression of cyclin D1, cylin G1, E2F1 were increased in L02/HBx-d382 cells compared with L02/pcDNA3.0 cells.(5) Based on the microRNA microarray, mir-1, mir-338-3p, mir-551b, miR-455-3p, and miR-200c were down-regulated, miR-501, miR-595, miR-1307, miR-1180, miR-497, miR-1246 and miR-623 were up-regulated in L02/HBx-d382 cells compared with the L02/ pcDNA3.0 cells.
Conclusion:L02 cell line stably expressing HBx deletion mutation (HBx-d382) is established successfully. HBx-deletion mutation(HBx-d382) can enhance the proliferation and anchorage-independent growth ability of L02 cells, and promotes cell cycle progression from G1 to the S phase, which may due to the increase gene expression of cyclin D1, cylin G1, E2F1 that are associated with G1 cell cycle control. This virus gene can also influence the microRNA expression profile in the 102 cells, which may be a new molecular biological mechanism of HBx-d382 induced hepatocytes malignant transformation.
方法：含HBx-d382的重组质粒(pcDNA3.0/HBx-d382)经过PCR(Polymerase chain reaction)扩增、双酶切及DNA测序鉴定后,通过脂质体转染和G418筛选获得稳定表达HBx-d382的L02肝细胞株,PCR鉴定L02细胞基因组中HBx-d382基因整合,RT-PCR(Reverse transcription polymerase chain reaction)和western blot鉴定其表达。通过MTT法,软琼脂克隆形成实验检测HBx-d382对L02细胞增殖及非锚定依赖生长能力的影响,用流式细胞仪检测其对细胞周期的影响；通过real-time定量PCR及western-blot鉴定转染HBx-d382后L02细胞cyclin D1,cylinG1,E2F1表达改变；通过microRNA芯片技术检测HBx-d382对L02细胞miRNA (microRNA)表达谱的影响。
结果：(1)经PCR、酶切及测序鉴定HBx-d382重组质粒构建正确。(2)稳定转染该质粒的L02细胞基因组存在HBx-d382整合,RT-PCR及Western-blot表明在RNA水平和蛋白水平存在HBx-d382表达。(3) MTT及软琼脂克隆形成实验结果表明稳定表达HBx-d382的L02细胞其增殖能力和非锚定生长能力增强,细胞周期检测证实转染HBx-d382的L02细胞S+G2期细胞比例升高。(4)real-time定量PCR结果表明与转染空质粒pcDNA3.0的L02细胞(L02/pcDNA3.0)相比L02/HBx-d382细胞cyclin D1, cylin G1, E2F1的mRNA表达明显增强(P<0.05);western-blot结果证实与102/pcDNA3.0细胞相比L02/HBx-d382细胞cyclin D1, cylin G1, E2F1蛋白表达明显增强(p<0.05) (5)microRNA芯片发现与L02/pcDNA3.0组细胞相比L02/HBx-d382组细胞mir-1,mir-338-3p, mir-551b, miR-455-3p, miR-200c表达下调,miR-501,miR-595, miR-1307, miR-1180, miR-497, miR-1246, miR-623表达上调。
结论：本研究成功的构建了HBx基因缺失突变体(HBx-d382)的真核表达模型,证实HBx-d382能增强L02细胞增殖及非锚定依赖生长能力。HBx-d382促使L02细胞打破G1期阻滞,进入S期,这种效应可能与其增强G1调控相关基因如cyclin D1, cylin G1, E2F1表达有关。HBx基因缺失突变体(HBx-d382)能影响L02肝细胞microRNA的表达谱,这为阐明HBx-d382致肝细胞恶性转化提供新的分子生物学机制。
Objective:Hepatocellular carcinoma (HCC) is a malignant tumor arising from hepatocytes; it is one of the most common malignancies worldwide. Epidemiological studies have showed that there is a strong relationship between the chronic hepatitis B virus infection and development of hepatocellular carcinoma, almost all of the HBV-associated HCCs harbor chromosomally integrated HBV DNA. In most integrated subviral HBV genomes, the HBx gene can be transcribed and translated into HBx protein, its significance in the hepatocarcinogenesis is be widely studied. our previous study has found that HBx gene integration and mutation occur frequently in HCC samples, and isolated two HBx deletion mutations naming HBx-d431 and HBx-d382(HBx gene nt 382-400 deletion),among which the HBx-d382 occurs more frequently in HCC samples, we guess it may be implicated in liver carcinogenesis, and then we have successfully constructed the eukaryotic expression vector for the expression of HBx-d382.In this study, we will establish a L02 cell line stably expressing HBx deletion mutation (HBx-d382) and further study the influence of HBx-d382 on cell proliferation,G1 cell cycle control and microRNA expression profile of L02 cells.
Methods:The recombinant plasmid encoding the HBx deletion mutation (pcDNA3.0/HBx-d382) was tested by PCR amplification、double digestion and DNA sequencing, and then introduced into L02 cells by liposome transfection. Positive clones were selected by G418. The genome integration of the HBx gene was test by PCR amplification, and the HBx expression was confirmed by reverse transcription PCR (RT-PCR) and western blot. Cell proliferation changes were measured by MTT assay and soft agar clone formation assay, and the cell cycles were tested by flow cytometry; the mRNA and protein expression of cyclin D1, cylin G1, E2F1 were detected by Real-time Quantitative PCR and Western blot respectively; microRNA expression profiles were analyzed by microRNA microarray.
Results:(1)The recombinant plasmid pcDNA3.0/HBx-d382 was successfully identified by PCR amplification、double digestion and DNA sequencing. (2)Positive clone that selected by G418 harbored chromosomally integrated HBx-d382; RT-PCR and Western blot confirmed the HBx expression at the mRNA and protein lever respectively.(3)This cell line showed enhanced proliferation and anchorage-independent growth ability when tested by MTT assay and soft agar clone formation assay; and the proportion of S and G2 phrase cells was increased simultaneously. (4)Real-time Quantitative PCR showed that the mRNA expression of cyclin D1, cylin G1, E2F1 were increased in L02/HBx-d382 cells compared with L02 cells transfected with the pcDNA3 empty plasmid(102/pcDNA3.0) (p<0.05); Western blot confirmed that the protein expression of cyclin D1, cylin G1, E2F1 were increased in L02/HBx-d382 cells compared with L02/pcDNA3.0 cells.(5) Based on the microRNA microarray, mir-1, mir-338-3p, mir-551b, miR-455-3p, and miR-200c were down-regulated, miR-501, miR-595, miR-1307, miR-1180, miR-497, miR-1246 and miR-623 were up-regulated in L02/HBx-d382 cells compared with the L02/ pcDNA3.0 cells.
Conclusion:L02 cell line stably expressing HBx deletion mutation (HBx-d382) is established successfully. HBx-deletion mutation(HBx-d382) can enhance the proliferation and anchorage-independent growth ability of L02 cells, and promotes cell cycle progression from G1 to the S phase, which may due to the increase gene expression of cyclin D1, cylin G1, E2F1 that are associated with G1 cell cycle control. This virus gene can also influence the microRNA expression profile in the 102 cells, which may be a new molecular biological mechanism of HBx-d382 induced hepatocytes malignant transformation.
引文
[1]Motola-Kuba D, Zamora-Valdes D, Uribe M,Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepatol JT-Annals of hepatology:official journal of the Mexican Association of Hepatology, 2006,5(1):16-24.
[2]Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med JT-The New England journal of medicine, 2004,350(11):1118-29.
[3]Zanetti AR, Van Damme P,Shouval D. The global impact of vaccination against hepatitis B:a historical overview. Vaccine JT-Vaccine,2008,26(49): 6266-73.
[4]Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer JT-International journal of cancer. Journal international du cancer,2006,118(12):3030-44.
[5]杨秉辉,夏景林,黄力文,汤钊猷,陈敏山,李锦清,梁安民,莫钦国,卢辉山,戴朝六,严律南 于志坚,饶荣生,黎乐群,苏智雄,方壮伟.我国肝癌”临床相”30年的变迁—原发性肝癌3250例的对比研究.中华医学杂志,2003,83：1053-1057.
[6]Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P,Patt YZ. Risk factors for hepatocellular carcinoma:synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology JT-Hepatology (Baltimore, Md.),2002,36(5):1206-13.
[7]Brechot C, Gozuacik D, Murakami Y,Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol JT-Seminars in cancer biology,2000,10(3): 211-31.
[8]Li JT, Liao ZX, Ping J, Xu D,Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol JT-Journal of gastroenterology,2008,43(6):419-28.
[9]Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT,Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA JT-JAMA:the journal of the American Medical Association,2006,295(1):65-73.
[10]Zheng Y, Chen WL, Louie SG, Yen TS,Ou JH. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology JT-Hepatology (Baltimore, Md.),2007,45(1):16-21.
[11]Soussan P, Garreau F, Zylberberg H, Ferray C, Brechot C,Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest JT-The Journal of clinical investigation,2000,105(1):55-60.
[12]Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett JT-Cancer letters,2009,286(1):52-9.
[13]Diao J, Garces R,Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev JT-Cytokine & growth factor reviews,2001,12(2-3):189-205.
[14]Minemura M, Shimizu Y, Hirano K, Nakayama Y, Tokimitsu Y, Tajiri K, Yamada K, Xue F, Takahara T, Watanabe A,Sugiyama T. Functional analysis of transactivation by mutants of hepatitis B virus X gene in human hepatocellular carcinoma. Oncol Rep JT-Oncology reports,2005,14(2): 495-9.
[15]Yeh CT, Shen CH, Tai DI, Chu CM,Liaw YF. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene JT-Oncogene, 2000,19(46):5213-20.
[16]Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, Kremsdorf D, Brechot C,Thiers V. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol JT-Journal of hepatology,2003,39(2):253-61.
[17]Zhang H, Shan CL, Li N, Zhang X, Zhang XZ, Xu FQ, Zhang S, Qiu LY, Ye LH,Zhang XD. Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation. Acta Pharmacol Sin JT-Acta pharmacologica Sinica,2008,29(4):473-80.
[18]Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA, Gao HJ,Zhu MH. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma. World J Gastroenterol JT-World journal of gastroenterology:WJG,2008,14(9):1346-52.
[19]Ma NF, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, Tzang CH, Fu L, Yang M, Su YA,Guan XY. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res JT-Clinical cancer research:an official journal of the American Association for Cancer Research,2008,14(16):5061-8.
[20]Liu X, Zhang S, Lin J, Zhang S, Feitelson MA, Gao H,Zhu M. Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem Biophys Res Commun JT-Biochemical and biophysical research communications,2008,373(4):643-7.
[21]Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR,Harris CC. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer JT-International journal of cancer. Journal international du cancer, 2009.
[22]Zhu P, Tan D, Peng Z, Liu F,Song L. Polymorphism analyses of hepatitis B virus X gene in hepatocellular carcinoma patients from southern China. Acta Biochim Biophys Sin (Shanghai) JT-Acta biochimica et biophysica Sinica, 2007,39(4):265-72.
[23]朱平安,谭德明,陈莉,彭忠田,宋琳.肝细胞癌组织中HBx基因缺失型突变体真核表达载体的构建和鉴定.热带医学杂志,2008,8.
[24]Massague J. G1 cell-cycle control and cancer. Nature JT-Nature, 2004,432(7015):298-306.
[25]Lee RC, Feinbaum RL,Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell JT-Cell, 1993,75(5):843-54.
[26]Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR,Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature JT-Nature,2000,403(6772):901-6.
[27]Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E,Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature JT-Nature,2000,408(6808):86-9.
[28]Lau NC, Lim LP, Weinstein EG,Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science JT-Science (New York, N.Y.),2001,294(5543):858-62.
[29]Lagos-Quintana M, Rauhut R, Lendeckel W,Tuschl T. Identification of novel genes coding for small expressed RNAs. Science JT-Science (New York, N.Y.),2001,294(5543):853-8.
[30]Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science JT-Science (New York, N.Y.),2001,294(5543):862-4.
[31]Bartel DP. MicroRNAs:genomics, biogenesis, mechanism, and function. Cell JT-Cell,2004,116(2):281-97.
[32]Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev JT-Current opinion in genetics & development, 2005,15(5):563-8.
[33]Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell JT-Developmental cell,2006,11(4): 441-50.
[34]Ambros V. The functions of animal microRNAs. Nature JT-Nature, 2004,431(7006):350-5.
[35]Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C,Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol JT-Genome biology, 2007,8(10):R214.
[36]Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM,Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell JT-Cancer cell,2006,9(3):189-98.
[37]Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL,Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res JT-Cancer research,2007,67(13):6130-5.
[38]Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ,Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer JT-International journal of cancer. Journal international du cancer,2007,120(5):1046-54.
[39]Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S,Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res JT-Cancer research,2008,68(10):3566-72.
[40]Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, Zeng WT, Cao LQ, Tan HX,Su Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma:miR-338 is downregulated. Hepatol Res JT-Hepatology research:the official journal of the Japan Society of Hepatology,2009,39(8):786-94.
[41]Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene JT-Oncogene,2006,25(46):6202-10.
[42]Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS,Hatton CS. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer JT International journal of cancer. Journal international du cancer,2007,121(5): 1156-61.
[43]Yi Z, Fu Y, Zhao S, Zhang X,Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol JT-Journal of cancer research and clinical oncology,2009.
[44]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.184-186.
[45]Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D,Brechot C. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene JT-Oncogene,2003,22(25):3911-6.
[46]Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet JT-Nature genetics,2002,31(4): 339-46.
[47]Schluter V, Meyer M, Hofschneider PH, Koshy R,Caselmann WH. Integrated hepatitis B virus X and 3'truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene JT Oncogene,1994,9(11):3335-44.
[48]Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol JT-Journal of virology,2004,78(23):12725-34.
[49]Tang H, Oishi N, Kaneko S,Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci JT-Cancer science, 2006,97(10):977-83.
[50]Wang Y, Lau SH, Sham JS, Wu MC, Wang T,Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinomas:association of truncated X gene and hepatocellular carcinogenesis. Oncogene JT-Oncogene,2004,23(1): 142-8.
[51]Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Brechot P, Brechot C,Kremsdorf D. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res JT-Cancer research,2001,61(21):7803-10.
[52]程斌,林松挺,杨玉珍,黎培员.转基因细胞模型L02/HBx的构建及HBx对细胞周期的影响.2007,15：1488-1493.
[53]Zhang WY, Cai N, Ye LH,Zhang XD. Transformation of human liver L-O2 cells mediated by stable HBx transfection. Acta Pharmacol Sin JT-Acta pharmacologica Sinica,2009,30(8):1153-61.
[54]Hou Z, Liu G, Zheng F,Tan D. HBx gene inducing hepatocellular carcinoma in vivo and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban JT-Zhong nan da xue xue bao. Yi xue ban= Journal of Central South University. Medical sciences,2009,34(4):282-8.
[55]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.274-286.
[56]斯佩克特等著,黄培堂主译.细胞实验指南.北京：科学出版社,2001.781-786.
[57]Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G,Xie K. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules:a key to the cell cycle and apoptosis. Int J Oncol JT-International journal of oncology,2005,26(2):467-73.
[58]Kim CM, Koike K, Saito I, Miyamura T,Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature JT-Nature,1991,351(6324): 317-20.
[59]Reifenberg K, Lohler J, Pudollek HP, Schmitteckert E, Spindler G, Kock J,Schlicht HJ. Long-term expression of the hepatitis B virus core-e-and X-proteins does not cause pathologic changes in transgenic mice. J Hepatol JT-Journal of hepatology,1997,26(1):119-30.
[60]Hussain SP, Schwank J, Staib F, Wang XW,Harris CC. TP53 mutations and hepatocellular carcinoma:insights into the etiology and pathogenesis of liver cancer. Oncogene JT-Oncogene,2007,26(15):2166-76.
[61]Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P,Buendia MA. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene JT-Oncogene,1997,14(4):395-404.
[62]Kim YC, Song KS, Yoon G, Nam MJ,Ryu WS. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene JT-Oncogene,2001,20(1): 16-23.
[63]Minami M, Daimon Y, Mori K, Takashima H, Nakajima T, Itoh Y,Okanoue T. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene JT-Oncogene,2005,24(27):4340-8.
[64]Wang Q, Zhang W, Liu Q, Zhang X, Lv N, Ye L,Zhang X. A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia JT-Neoplasia (New York, N.Y.),2010,12(2):103-15.
[65]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.186-187.
[66]Helgason CD, Miller CL. Basic cell culture protocols.3rd ed. New Jersey: Humana Press,2002:72.
[67]Prasanth SG, Mendez J, Prasanth KV,Stillman B. Dynamics of pre-replication complex proteins during the cell division cycle. Philos Trans R Soc Lond B Biol Sci JT-Philosophical transactions of the Royal Society of London. Series B, Biological sciences,2004,359(1441):7-16.
[68]Murray AW. Recycling the cell cycle:cyclins revisited. Cell JT-Cell, 2004,116(2):221-34.
[69]Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol JT-Current opinion in cell biology, 2002,14(6):684-91.
[70]van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol JT-Nature reviews. Molecular cell biology,2008,9(9): 713-24.
[71]Seville LL, Shah N, Westwell AD,Chan WC. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets JT-Current cancer drug targets,2005,5(3):159-70.
[72]Fu M, Wang C, Li Z, Sakamaki T,Pestell RG. Minireview:Cyclin D1:normal and abnormal functions. Endocrinology JT-Endocrinology,2004,145(12): 5439-47.
[73]Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M,Graessmann A. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. Oncogene JT-Oncogene, 2003,22(19):2910-9.
[74]Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM,Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology JT-Hepatology (Baltimore, Md.),2006,44(4):1003-11.
[75]Choi BH, Choi M, Jeon HY,Rho HM. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol JT-DNA and cell biology,2001,20(2):75-80.
[76]Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G,Grassi G. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie JT-Biochimie, 2009,91(3):373-82.
[77]Jung JK, Arora P, Pagano JS,Jang KL. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res JT-Cancer research,2007,67(12):5771-8.
[78]Ohtsuka T, Jensen MR, Kim HG, Kim KT,Lee SW. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene JT-Oncogene,2004,23(31): 5405-8.
[79]Jensen MR, Factor VM, Fantozzi A, Helin K, Huh CG,Thorgeirsson SS. Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology JT-Hepatology (Baltimore, Md.),2003,37(4):862-70.
[80]Baek WK, Kim D, Jung N, Yi YW, Kim JM, Cha SD, Bae I,Cho CH. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am J Obstet Gynecol JT-American journal of obstetrics and gynecology, 2003,188(3):634-9.
[81]Kwon SH, Park JC, Ramachandran S, Cha SD, Kwon KY, Park JK, Park JW, Bae I,Cho CH. Loss of cyclin g1 expression in human uterine leiomyoma cells induces apoptosis. Reprod Sci JT-Reproductive sciences (Thousand Oaks, Calif.),2008,15(4):400-10.
[82]Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M,Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res JT-Cancer research, 2009,69(14):5761-7.
[83]Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene JT-Oncogene,2000,19(3):468-71.
[84]84 Li W, Miao X, Qi Z, Zeng W, Liang J,Liang Z. Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. Virol J JT-Virology journal,2010,7:45.
[85]Chan DW, Ng IO. Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol JT-The Journal of pathology,2006,208(3):372-80.
[86]Park SG, Chung C, Kang H, Kim JY,Jung G. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem JT-The Journal of biological chemistry, 2006,281(42):31770-7.
[87]Kim HR, Lee SH,Jung G. The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1. FEBS Lett JT-FEBS letters,2010,584(3):525-30.
[88]Lewis BP, Burge CB,Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell JT-Cell,2005,120(1):15-20.
[89]Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2004,101(9):2999-3004.
[90]Kluiver J, Kroesen BJ, Poppema S,van den Berg A. The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia JT Leukemia:official journal of the Leukemia Society of America, Leukemia Research Fund, U.K,2006,20(11):1931-6.
[91]Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell JT-Cell,2008,133(2):217-22.
[92]Medina PP, Slack FJ. microRNAs and cancer:an overview. Cell Cycle JT-Cell cycle (Georgetown, Tex.),2008,7(16):2485-92.
[93]Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F,Croce CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR 16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2002,99(24):15524-9.
[94]Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E,Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol JT-Nature cell biology,2008,10(2):202-10.
[95]Ma L, Teruya-Feldstein J,Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature JT-Nature, 2007,449(7163):682-8.
[96]Park SM, Gaur AB, Lengyel E,Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev JT-Genes & development,2008,22(7):
894-907.
[97]Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL,Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature JT-Nature,2008,451(7175):147-52.
[98]Bartel DP. MicroRNAs:target recognition and regulatory functions. Cell JT Cell,2009,136(2):215-33.
[99]99 Carleton M, Cleary MA,Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle JT-Cell cycle (Georgetown, Tex.),2007,6(17):2127-32.
[100]Ventura A, Jacks T. MicroRNAs and cancer:short RNAs go a long way. Cell JT-Cell,2009,136(4):586-91.
[101]Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M,Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2004,101(32):11755-60.
[102]Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ,Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res JT-Nucleic acids research,2005,33(20):el79.
[103]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR,Golub TR. MicroRNA expression profiles classify human cancers. Nature JT-Nature,2005,435(7043):834-8.
[104]Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B,Velculescu VE. The colorectal microRNAome. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2006,103(10):3687-92.
[105]Thompson RC, Deo M,Turner DL. Analysis of microRNA expression by in situ hybridization with RNA oligonucleotide probes. Methods JT-Methods (San Diego, Calif.),2007,43(2):153-61.
[106]Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue
T,Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene JT-Oncogene, 2006,25(17):2537-45.
[107]Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M,Hu CX. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol JT Journal of gastroenterology and hepatology,2008,23(1):87-94.
[108]Zorio E, Medina P, Rueda J, Millan JM, Arnau MA, Beneyto M, Marin F, Gimeno JR, Osca J, Salvador A, Espana F,Estelles A. Insights into the role of microRNAs in cardiac diseases:from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem JT-Cardiovascular & hematological agents in medicinal chemistry,2009,7(1):82-90.
[109]Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J,Tu L. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem JT-The Journal of biological chemistry,2009,284(43): 29596-604.
[110]Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST,Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem JT The Journal of biological chemistry,2008,283(48):33394-405.
[111]Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN,Steer CJ. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer JT-BMC cancer,2009,9:401.
[112]Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM,Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res JT-Cancer research,2008,68(15): 6162-70.
[113]Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG,
Volinia S, Croce CM, Schmittgen TD, Ghoshal K,Jacob ST. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res JT-Cancer research,2008,68(13):5049-58.
[114]Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, Terasawa K, Sato F, Tsujimoto G,Shimizu K. MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells. Nucleic Acids Res JT Nucleic acids research,2009,37(11):3821-7.
[115]Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QS, Xin M, Wang F, Appel B,Lu QR. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron JT-Neuron,2010,65(5):612-26.
[116]Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR,Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res JT-Cancer research, 2007,67(6):2456-68.
[117]L X, Z Y, Z Y, D J, W K,F D. Survival Prediction of Gastric Cancer by a Seven-microRNA Signature. Gut JT-Gut,2009.
[118]Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM,Yi XZ. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res JT-Journal of experimental & clinical cancer research:CR,2009,28:64.
[119]Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C,Lui WO. MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. J Invest Dermatol JT-The Journal of investigative dermatology,2010.
[120]Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M,Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol JT-The Journal of pathology,2008,216(4):418-27.
[121]Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz
S,Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol JT-Nature cell biology, 2009,11(12):1487-95.
[122]Tryndyak VP, Beland FA,Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer JT-International journal of cancer. Journal international du cancer, 2010,126(11):2575-83.
[123]Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA,Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res JT-Cancer research,2009,69(16):6704-12.
[124]Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA,Summerhayes IC. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol JT-Urologic oncology,2009.
[125]Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK,Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther JT Molecular cancer therapeutics,2009.
[126]Yang SZ, Zhang LD, Zhang Y, Xiong Y, Zhang YJ, Li HL, Li XW,Dong JH. HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun JT-Biochemical and biophysical research communications,2009,382(3):555-60.
[127]Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR,Futscher BW. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One JT-PloS one, 2010,5(1):e8697.
[128]Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K,Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell JT-Cell,2009,138(3):592-603.
[129]Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI,Kovalchuk
O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer JT International journal of cancer. Journal international du cancer,2010.
[130]Cochrane DR, Howe EN, Spoelstra NS,Richer JK. Loss of miR-200c:A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol JT-Journal of oncology,2010,2010:821717.
[131]Wan Q, Kuang E, Dong W, Zhou S, Xu H, Qi Y,Liu Y. Reticulon 3 mediates Bcl-2 accumulation in mitochondria in response to endoplasmic reticulum stress. Apoptosis JT-Apoptosis:an international journal on programmed cell death,2007,12(2):319-28.
[132]Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D,Lagneaux L. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood JT-Blood,2009,113(21):5237-45.
[133]Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S,Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res JT-Cancer research,2010,70(5):1916-24.
[134]Wang G, Zhang H, He H, Tong W, Wang B, Liao G, Chen Z,Du C. Up-regulation of microRNA in bladder tumor tissue is not common. Int Urol Nephrol JT-International urology and nephrology,2010,42(1):95-102.
[135]Park SY, Lee JH, Ha M, Nam JW,Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol JT-Nature structural & molecular biology,2009,16(1):23-9.
[136]Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS,Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem JT-The Journal of biological chemistry, 2009,284(9):5731-41.
[137]Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A,Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem
cells. BMC Med JT-BMC medicine,2008,6:14.
[138]Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM,Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell JT-Cancer cell,2008,13(3):272-86.
[139]Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ,Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA JT-RNA (New York, N.Y.),2008,14(1):35-42.
[140]Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR,Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res JT-Clinical cancer research:an official journal of the American Association for Cancer Research,2008,14(2):419-27.
[141]Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K,Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology JT-Hepatology (Baltimore, Md.),2009,49(4): 1098-112.
[1]Bartel DP. MicroRNAs:genomics,biogenesis,mechanism,and function. Cell, 2004,116(2):281.
[2]Zamore PD, Haley B. Ribo-gnome:the big world of small RNAs. Science, 2005,309 (5740):1519-1524.
[3]Krutzfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet,2006,38 Suppl:S14-19.
[4]McManus MT. MicroRNAs and cancer. Semin Cancer Biol,2003,13(4): 253-258.
[5]Lee RC, Feinbaum RL, Ambros V C, et al. The heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell,1993, 75(5):843-854.
[6]Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006,6(11):857.
[7]Hwang HW, Mendell JT. microRNAs in cell proliferation,cell death,and tumorigenesis. Br J Cancer,2006,94(6):776-780.
[8]Jovanovic M, Hengartner MO. miRNAs and apoptosis:RNAs to die for. Oncogene,2006,25(46):6176-6187.
[9]Lu Y, Thomson JM, Wong HY, et al. Transgenic over-expression of the microRNAmiR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol,2007,310(2):442-453.
[10]He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature,2005,316(5824):604.
[11]Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev,2006,16(1): 4-9.
[12]Esquela-Kerseher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer,2006,6(4):259-269.
[13]Cho WC. OncomiRs:the discovery and progress of microRNAs in cancers. Mol Cancer,2007,6:60.
[14]Reinhart BJ, Slack FJ, Basson M, et al. The 21 nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature,2000,403(6772): 901-906.
[15]Cummins JM, He Y, Leary RJ,et al. The colorectal microRNAome. Proc Natl Acad Sci USA,2006,103(10):3687-3692.
[16]Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature,2004,432(7014):231-235.
[17]Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science,2004,303(5654):95-98.
[18]Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA, 2004,10(2):185-191.
[19]Ouellet DL, Perron MP, Gobeil LA, et al. MicroRNAs in gene regulation:when the smallest governs it all. J Biomed Biotechnol,2006,2006(4):69616.
[20]Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature,2005, 433(7027):769-773.
[21]Brennecke J, Stark A, Russell RB, et al. Principles of microRNA target recognition. PLoS Biol,2005,3(3):e85.
[22]Xiao L, Rao JN, Zou T, et al. Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol Biol Cell,2007,18(11):4579-4590.
[23]Lai EC. Micro RNAs are complementary to 3'UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet,2002,30(4): 363-364.
[24]Kim VN. Small RNAs:classification, biogenesis, and function. Mol Cells,2005, 19(1):1-15.
[25]Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev,2006,20(5):515-524.
[26]Wu L, Fan J, Belasco JG MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A,2006,103(11):4034-4039.
[27]Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science,2005,309(5740): 1577-1581.
[28]Esquela-Kerseher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev cancer,2006,6(4):259-269.
[29]Schmittgen TD, Jiang J, Liu Q, et al. A high-through put method to monitor the expression of microRNA precursors. Nucleic Acids Res,2004,32(4):e43.
[30]Chen C, Ridzon DA, Broomer AJ, et al. Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res,2005,33(21):e183.
[31]Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human andmouse tissues. Proc Natl Acad Sci U S A,2004,101(26):9740-9744.
[32]Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A,2002,99(24):15524-15529.
[33]O'Donnell KA, Wentzel EA, Zeller KI, et al. C-Myc-regulated microRNAs modulate E2F1 expression. Nature,2005,435(7043):839-843.
[34]Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A,2006, 103(7):2257-2261.
[35]Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature,2005,435(7043):834-838.
[36]Vinther J, Hedegaard MM, Gardner PP, et al. Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res, 2006,34(16):e107.
[37]Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol,2008,141(5):672-675.
[38]Mitchell PS, Porkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A,2008, 105(30):10513-10518.
[39]Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell,2003,115 (7):787-798.
[40]Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res,2005,65(16):7065-7070.
[41]Metzler M, Wilda M, Busch K, et al. High expression of precursor microRNA-155/B IC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer,2004,39 (2):167-169.
[42]Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A,2005,102(10):3627-3632.
[43]Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun,2005, 334(4):1351-1358.
[44]Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an anti-apoptotic factor in human glioblastoma cells. Cancer Res,2005,65(14):6029-6033.
[45]Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res,2004,64(11):3753-3756.
[46]Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancermetastasis. Nature,2008,451(10):147-152.
[47]Cimmino A, Calin GA, Fabbri M, et al. MiR-15 and miR-16 induce apoptosis by targeting BCL-2. Proc Natl Acad Sci U S A,2005,102(39):13944-13949.
[48]Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A,2004,101(9):2999-3004.
[49]Motola-Kuba D, Zamora-Valdes D, Uribe M, et al. Hepatocellular carcinoma. An overview. Ann Hepatol,2006,5(1):16-24.
[50]Levrero M. Viral hepatitis and liver cancer:the case of hepatitis C. Oncogene, 2006,25(27):3834-3847.
[51]Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology,2004,40(3): 667-676.
[52]Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res,2008,14(2):419-427.
[53]Roberts LR, Gores GJ. Hepatocellular carcinoma:molecular pathways and new therapeutic targets. Semin Liver Dis,2005,25(2):212-225.
[54]Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene,2006,25(17):2537-2545.
[55]Wang Y, Lee A T, Ma J Z, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem,2008,283(19): 13205-13215.
[56]Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem,2006,99(3):671-678.
[57]Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology,2007,133(2):647-658.
[58]Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res,2007,67(13):6092-6099.
[59]Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008,27(43):5651-5661.
[60]Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology,2008,47(4): 1223-1232.
[61]Huang YS, Dai Y, Yu XF, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol,2008,23(1):87-94.
[62]Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology,2008,47(6):1955-1963.
[63]Gupta GP, Massague J. Cancermetastasis:building a framework. Cell,2006, 127(4):679-695.
[64]Wu X, Fan J, Wang X, et al. Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. Biochem Biophys Res Commun,2007, 355(4):866-871.
[65]Budhu A, Jia H L, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology,2008,47(3):897-907.
[66]Li W, Xie L, He X, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer,2008,123(7):1616-1622.
[67]Si ML, Zhu S,Wu H, et al. miR-21-mediated tumor growth. Oncogene,2007, 26(19):2799-2803.
[68]Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with'antagomirs'. Nature,2005,438(7068):685-689.
[1]GARCIA-TSAO G,SANYAL AJ,GRACE ND,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrh-osis[J]. Hepatology,2007,46(3):922-38.
[2]GARCIA-TSAO G, GROSZMANN RJ, FISHER RL,et al Portal pressure, presence of gastroesophageal varices and ariceal bleeding[J]. HEP-ATOLOGY,1985,5:419-424.
[3]ABRALDES JG, TARANTINO I, TURNES J, et al. Hmodynamic response to pharmacological treatment of portal hypertension And longte-rm prognosis of cirrhosis[J].HEPATOLOGY,2003,37:902-908.
[4]D'AMICO G, GARCIA-PAGAN JC, LUCA A, at al. HVPG reduction and prevention of variceal bleeding in cirrhosis. A systematic revie-w[J]. Gastroenterology,2006,13(5):1611-24.
[5]ALBILLOS A,BANARES R,CONZALZ M,et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis[J]. Am J Gastroenterol,2007,102(5):1116-26.
[6]D'AMICO G, PAGLIARO L, BOSCH J,et al. Pharmacological treatment of portal hypertension:an evidence-based approach[J]. Semin Liver Dis,1999, 19:475-505
[7]DE FRANCHIS R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol,2005,43:167-176.
[8]MERKEL C, MARTN R,ANGELI P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis[J].Gastroenterology,2004,127(2):476-84.
[9]GROSZMANN RJ, GARCIA-TSAO G,BOSCH J,et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J].N Engl J Med,2005, 353:2254-2261.
[10]D'AMICO G, GARCIA-TSAO G, CALES P, et al. Diagnosis of portal hypertension:how and when. In:de Franchis R.Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies[J]. Oxford, UK: Blackwell Science,2001:36-64.
[11]DIANE R. ABRACZINSKAS, RIE OOKUBO,et al.Propranolol for the Prevention of First Esophageal Variceal Hemorrhage:A Lifetime Commitment?[J].HEPATOLOGY,2001,34:1096-1102
[12]LO GH, CHEN WC, CHEN MH,et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis[J].Gastrointest Endosc,2004,59:333-338.
[13]SCHEPKE M, KLEBER G, NURNBERG D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis [J]. HEPATOLOGY,2004,40:65-72.
[14]LAY CS, TSAI YT, LEE FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis[J]. J Gastroenterol Hepatol,2006,21:413-419.
[15]ANNA V, LONGACRE, AVLIN IMAEDA,et al. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage[J].hepatology,2008,47(l):169-76.
[16]JUTABHA R, JENSEN DM, MARTIN P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices[J]. Gastroenterology,2005,128:870-81
[17]BUREAU C, PERON JM, ALRIC L, et al. "A la Carte" treatment of portal hypertension:adapting medical therapy to hemodynamic response for the prevention of bleeding [J]. HEPATOLOGY,2002,36:1361-1366.
[18]BOSCH J. A la carte or menu fixe:Improving pharmacologic therapy of portal hypertension[J].Hepatology,2002,36:1330-1332.
[19]GARCIA-PAGAN JC, VILLANUEVA C, VILA MC, et al. Mononitrato Varices Esofagicas:Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers[J]. Gastroenterology, 2001,121:908-914.
[20]BORRONI G, SALERNO F, CAZZANIGA M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites[J]. J Hepatol,2002,37(3):315-21.
[21]LUI HF, STANLEY AJ, FOREST EH, et al Primary prophylaxis of variceal hemorrhage:a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate[J].Gastroenterology,2002,123 (3): 735-44
[22]ANGELICO M,CARLI L, PIAT C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis[J]. Gastroen-terology,1993,104:1460-1465
[23]ANGELICO M,CARLI L, PIAT C, et al Effects of Isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis[J]. Gastroenterology,1997,113:1632-1639.
[24]MERKEL C, MARTN R, ENZO E, et al.Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)[J]. lancet,1996, 348(9043):1677-81
[25]MERKEL C,MARIN R, ENZO E, et al Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis[J]. Hepatology,2000,31(2):324-9.
[26]JUAN CARLOS, GARCFA-PAG'AN, ROSA MORILLAS, et al.Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed:a double-blind RCT[J].Hepatology, 2003,37(6):1260-6.
[27]POZZI M, GRASSI G, RATTI L, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child a cirrhosis[J]. Am J Gastroenterol,2005,100(5):1110-1116
[28]BOLONDI L, PISCAGLIA F, GATTA A, et al.Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis[J]. Clin Gastroenterol Hepatol,2006,4(11):1395-402.
[29]NEVENS F, LIJNEN P, VANBILLOEN H, et al The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites[J].Hepatology,1996,23(5):1047-52
[30]SEN S, DE BK, BISWAS PK, et al.One in liver cirrhosis and propranolol-resistant portal hypertension[J].Indian J Gastroenterol,2002,21 (4):145-8
[31]ABECASIS R, KRAVETZ D, FASSIO E, et al Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients:A preliminary study[J].Hepatology,2003,37(2):359-65
[32]左文革,王春平.薛兴存食管静脉曲张首次出血前药物干预的随机对照研究[J].肝脏,2007,12(05)：342-345
[33]BANARES R, MOITINHO E,MATILLA A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. HEPATOLOGY,2002,36:1367-1373
[34]LIN HC, YANG YY, HOU MC, et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis[J].Am J Gastroenterol,2004,99:1953-1958
[35]PERELLO A, ESCORSELL A, BRU C,et al Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis [J]. HEPATOLOGY,1999,30:1393-1397.
[36]GROSZMANN RJ, WONGCHARATRAWEE S. The hepatic venous pressure gradient:Anything worth doing should be done right[J]. HEPATOLOGY, 2004,39:280-283.
[37]GARCIA-PAGAN JC, SANTOS C, BARBERA JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portalhypertension[J]. Gastroenterology,1996,111:1300-1306.
[38]MCCORMICK PA, DICK R, GRAFFEO M, et al. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patientswith cirrhosis[J]. J Hepatol,1990,11:221-225.
[39]MILLER LS, KIM JK, DAI Q, et al. Mechanics and hemodynamics of esophageal varices during peristaltic contraction[J]. Am J PhysiolGastrointest Liver Physiol,2004,287:G830-G835.
[40]OKUDA K, KONO K, OHNISHI K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly [J]. Gastroenterology,1984,86:600-610.
[41]THALHEIMER U, TRIANTOS C, SAMONAKIS D, et al. Infection, coagulation and variceal bleeding in cirrhosis. A review[J]. Gut,2005, 54:556-563
[42]PEREZ-PARAMO M, MUNOZ J,ALBILLOS A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites[J]. Hepatology,2000,31:43-48.
[43]CHOLONGITAS E,PAPATHEODORIDIS GV,MANESIS EK, et al. Spontaneos bacterial peritonitis in cirrhotic patients:is prophylactic propranolol therapy beneficial?[J] J Gastroenterol Hepatol,2006,21:581-587.
[2]Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med JT-The New England journal of medicine, 2004,350(11):1118-29.
[3]Zanetti AR, Van Damme P,Shouval D. The global impact of vaccination against hepatitis B:a historical overview. Vaccine JT-Vaccine,2008,26(49): 6266-73.
[4]Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer JT-International journal of cancer. Journal international du cancer,2006,118(12):3030-44.
[5]杨秉辉,夏景林,黄力文,汤钊猷,陈敏山,李锦清,梁安民,莫钦国,卢辉山,戴朝六,严律南 于志坚,饶荣生,黎乐群,苏智雄,方壮伟.我国肝癌”临床相”30年的变迁—原发性肝癌3250例的对比研究.中华医学杂志,2003,83：1053-1057.
[6]Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P,Patt YZ. Risk factors for hepatocellular carcinoma:synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology JT-Hepatology (Baltimore, Md.),2002,36(5):1206-13.
[7]Brechot C, Gozuacik D, Murakami Y,Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol JT-Seminars in cancer biology,2000,10(3): 211-31.
[8]Li JT, Liao ZX, Ping J, Xu D,Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol JT-Journal of gastroenterology,2008,43(6):419-28.
[9]Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT,Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA JT-JAMA:the journal of the American Medical Association,2006,295(1):65-73.
[10]Zheng Y, Chen WL, Louie SG, Yen TS,Ou JH. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology JT-Hepatology (Baltimore, Md.),2007,45(1):16-21.
[11]Soussan P, Garreau F, Zylberberg H, Ferray C, Brechot C,Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest JT-The Journal of clinical investigation,2000,105(1):55-60.
[12]Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett JT-Cancer letters,2009,286(1):52-9.
[13]Diao J, Garces R,Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev JT-Cytokine & growth factor reviews,2001,12(2-3):189-205.
[14]Minemura M, Shimizu Y, Hirano K, Nakayama Y, Tokimitsu Y, Tajiri K, Yamada K, Xue F, Takahara T, Watanabe A,Sugiyama T. Functional analysis of transactivation by mutants of hepatitis B virus X gene in human hepatocellular carcinoma. Oncol Rep JT-Oncology reports,2005,14(2): 495-9.
[15]Yeh CT, Shen CH, Tai DI, Chu CM,Liaw YF. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene JT-Oncogene, 2000,19(46):5213-20.
[16]Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, Kremsdorf D, Brechot C,Thiers V. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol JT-Journal of hepatology,2003,39(2):253-61.
[17]Zhang H, Shan CL, Li N, Zhang X, Zhang XZ, Xu FQ, Zhang S, Qiu LY, Ye LH,Zhang XD. Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation. Acta Pharmacol Sin JT-Acta pharmacologica Sinica,2008,29(4):473-80.
[18]Liu XH, Lin J, Zhang SH, Zhang SM, Feitelson MA, Gao HJ,Zhu MH. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma. World J Gastroenterol JT-World journal of gastroenterology:WJG,2008,14(9):1346-52.
[19]Ma NF, Lau SH, Hu L, Xie D, Wu J, Yang J, Wang Y, Wu MC, Fung J, Bai X, Tzang CH, Fu L, Yang M, Su YA,Guan XY. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res JT-Clinical cancer research:an official journal of the American Association for Cancer Research,2008,14(16):5061-8.
[20]Liu X, Zhang S, Lin J, Zhang S, Feitelson MA, Gao H,Zhu M. Hepatitis B virus X protein mutants exhibit distinct biological activities in hepatoma Huh7 cells. Biochem Biophys Res Commun JT-Biochemical and biophysical research communications,2008,373(4):643-7.
[21]Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR,Harris CC. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer JT-International journal of cancer. Journal international du cancer, 2009.
[22]Zhu P, Tan D, Peng Z, Liu F,Song L. Polymorphism analyses of hepatitis B virus X gene in hepatocellular carcinoma patients from southern China. Acta Biochim Biophys Sin (Shanghai) JT-Acta biochimica et biophysica Sinica, 2007,39(4):265-72.
[23]朱平安,谭德明,陈莉,彭忠田,宋琳.肝细胞癌组织中HBx基因缺失型突变体真核表达载体的构建和鉴定.热带医学杂志,2008,8.
[24]Massague J. G1 cell-cycle control and cancer. Nature JT-Nature, 2004,432(7015):298-306.
[25]Lee RC, Feinbaum RL,Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell JT-Cell, 1993,75(5):843-54.
[26]Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR,Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature JT-Nature,2000,403(6772):901-6.
[27]Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E,Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature JT-Nature,2000,408(6808):86-9.
[28]Lau NC, Lim LP, Weinstein EG,Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science JT-Science (New York, N.Y.),2001,294(5543):858-62.
[29]Lagos-Quintana M, Rauhut R, Lendeckel W,Tuschl T. Identification of novel genes coding for small expressed RNAs. Science JT-Science (New York, N.Y.),2001,294(5543):853-8.
[30]Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science JT-Science (New York, N.Y.),2001,294(5543):862-4.
[31]Bartel DP. MicroRNAs:genomics, biogenesis, mechanism, and function. Cell JT-Cell,2004,116(2):281-97.
[32]Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev JT-Current opinion in genetics & development, 2005,15(5):563-8.
[33]Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell JT-Developmental cell,2006,11(4): 441-50.
[34]Ambros V. The functions of animal microRNAs. Nature JT-Nature, 2004,431(7006):350-5.
[35]Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C,Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol JT-Genome biology, 2007,8(10):R214.
[36]Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM,Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell JT-Cancer cell,2006,9(3):189-98.
[37]Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL,Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res JT-Cancer research,2007,67(13):6130-5.
[38]Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ,Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer JT-International journal of cancer. Journal international du cancer,2007,120(5):1046-54.
[39]Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S,Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res JT-Cancer research,2008,68(10):3566-72.
[40]Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, Zeng WT, Cao LQ, Tan HX,Su Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma:miR-338 is downregulated. Hepatol Res JT-Hepatology research:the official journal of the Japan Society of Hepatology,2009,39(8):786-94.
[41]Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene JT-Oncogene,2006,25(46):6202-10.
[42]Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS,Hatton CS. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer JT International journal of cancer. Journal international du cancer,2007,121(5): 1156-61.
[43]Yi Z, Fu Y, Zhao S, Zhang X,Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol JT-Journal of cancer research and clinical oncology,2009.
[44]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.184-186.
[45]Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D,Brechot C. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene JT-Oncogene,2003,22(25):3911-6.
[46]Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet JT-Nature genetics,2002,31(4): 339-46.
[47]Schluter V, Meyer M, Hofschneider PH, Koshy R,Caselmann WH. Integrated hepatitis B virus X and 3'truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene JT Oncogene,1994,9(11):3335-44.
[48]Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol JT-Journal of virology,2004,78(23):12725-34.
[49]Tang H, Oishi N, Kaneko S,Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci JT-Cancer science, 2006,97(10):977-83.
[50]Wang Y, Lau SH, Sham JS, Wu MC, Wang T,Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinomas:association of truncated X gene and hepatocellular carcinogenesis. Oncogene JT-Oncogene,2004,23(1): 142-8.
[51]Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Brechot P, Brechot C,Kremsdorf D. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res JT-Cancer research,2001,61(21):7803-10.
[52]程斌,林松挺,杨玉珍,黎培员.转基因细胞模型L02/HBx的构建及HBx对细胞周期的影响.2007,15：1488-1493.
[53]Zhang WY, Cai N, Ye LH,Zhang XD. Transformation of human liver L-O2 cells mediated by stable HBx transfection. Acta Pharmacol Sin JT-Acta pharmacologica Sinica,2009,30(8):1153-61.
[54]Hou Z, Liu G, Zheng F,Tan D. HBx gene inducing hepatocellular carcinoma in vivo and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban JT-Zhong nan da xue xue bao. Yi xue ban= Journal of Central South University. Medical sciences,2009,34(4):282-8.
[55]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.274-286.
[56]斯佩克特等著,黄培堂主译.细胞实验指南.北京：科学出版社,2001.781-786.
[57]Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G,Xie K. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules:a key to the cell cycle and apoptosis. Int J Oncol JT-International journal of oncology,2005,26(2):467-73.
[58]Kim CM, Koike K, Saito I, Miyamura T,Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature JT-Nature,1991,351(6324): 317-20.
[59]Reifenberg K, Lohler J, Pudollek HP, Schmitteckert E, Spindler G, Kock J,Schlicht HJ. Long-term expression of the hepatitis B virus core-e-and X-proteins does not cause pathologic changes in transgenic mice. J Hepatol JT-Journal of hepatology,1997,26(1):119-30.
[60]Hussain SP, Schwank J, Staib F, Wang XW,Harris CC. TP53 mutations and hepatocellular carcinoma:insights into the etiology and pathogenesis of liver cancer. Oncogene JT-Oncogene,2007,26(15):2166-76.
[61]Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P,Buendia MA. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene JT-Oncogene,1997,14(4):395-404.
[62]Kim YC, Song KS, Yoon G, Nam MJ,Ryu WS. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene JT-Oncogene,2001,20(1): 16-23.
[63]Minami M, Daimon Y, Mori K, Takashima H, Nakajima T, Itoh Y,Okanoue T. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene JT-Oncogene,2005,24(27):4340-8.
[64]Wang Q, Zhang W, Liu Q, Zhang X, Lv N, Ye L,Zhang X. A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. Neoplasia JT-Neoplasia (New York, N.Y.),2010,12(2):103-15.
[65]司徒镇强,吴军正.细胞培养.西安：世界图书出版公司,1996.186-187.
[66]Helgason CD, Miller CL. Basic cell culture protocols.3rd ed. New Jersey: Humana Press,2002:72.
[67]Prasanth SG, Mendez J, Prasanth KV,Stillman B. Dynamics of pre-replication complex proteins during the cell division cycle. Philos Trans R Soc Lond B Biol Sci JT-Philosophical transactions of the Royal Society of London. Series B, Biological sciences,2004,359(1441):7-16.
[68]Murray AW. Recycling the cell cycle:cyclins revisited. Cell JT-Cell, 2004,116(2):221-34.
[69]Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol JT-Current opinion in cell biology, 2002,14(6):684-91.
[70]van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol JT-Nature reviews. Molecular cell biology,2008,9(9): 713-24.
[71]Seville LL, Shah N, Westwell AD,Chan WC. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets JT-Current cancer drug targets,2005,5(3):159-70.
[72]Fu M, Wang C, Li Z, Sakamaki T,Pestell RG. Minireview:Cyclin D1:normal and abnormal functions. Endocrinology JT-Endocrinology,2004,145(12): 5439-47.
[73]Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M,Graessmann A. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. Oncogene JT-Oncogene, 2003,22(19):2910-9.
[74]Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM,Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology JT-Hepatology (Baltimore, Md.),2006,44(4):1003-11.
[75]Choi BH, Choi M, Jeon HY,Rho HM. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol JT-DNA and cell biology,2001,20(2):75-80.
[76]Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G,Grassi G. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie JT-Biochimie, 2009,91(3):373-82.
[77]Jung JK, Arora P, Pagano JS,Jang KL. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res JT-Cancer research,2007,67(12):5771-8.
[78]Ohtsuka T, Jensen MR, Kim HG, Kim KT,Lee SW. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene JT-Oncogene,2004,23(31): 5405-8.
[79]Jensen MR, Factor VM, Fantozzi A, Helin K, Huh CG,Thorgeirsson SS. Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology JT-Hepatology (Baltimore, Md.),2003,37(4):862-70.
[80]Baek WK, Kim D, Jung N, Yi YW, Kim JM, Cha SD, Bae I,Cho CH. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am J Obstet Gynecol JT-American journal of obstetrics and gynecology, 2003,188(3):634-9.
[81]Kwon SH, Park JC, Ramachandran S, Cha SD, Kwon KY, Park JK, Park JW, Bae I,Cho CH. Loss of cyclin g1 expression in human uterine leiomyoma cells induces apoptosis. Reprod Sci JT-Reproductive sciences (Thousand Oaks, Calif.),2008,15(4):400-10.
[82]Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M,Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res JT-Cancer research, 2009,69(14):5761-7.
[83]Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene JT-Oncogene,2000,19(3):468-71.
[84]84 Li W, Miao X, Qi Z, Zeng W, Liang J,Liang Z. Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. Virol J JT-Virology journal,2010,7:45.
[85]Chan DW, Ng IO. Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol JT-The Journal of pathology,2006,208(3):372-80.
[86]Park SG, Chung C, Kang H, Kim JY,Jung G. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem JT-The Journal of biological chemistry, 2006,281(42):31770-7.
[87]Kim HR, Lee SH,Jung G. The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1. FEBS Lett JT-FEBS letters,2010,584(3):525-30.
[88]Lewis BP, Burge CB,Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell JT-Cell,2005,120(1):15-20.
[89]Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2004,101(9):2999-3004.
[90]Kluiver J, Kroesen BJ, Poppema S,van den Berg A. The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia JT Leukemia:official journal of the Leukemia Society of America, Leukemia Research Fund, U.K,2006,20(11):1931-6.
[91]Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell JT-Cell,2008,133(2):217-22.
[92]Medina PP, Slack FJ. microRNAs and cancer:an overview. Cell Cycle JT-Cell cycle (Georgetown, Tex.),2008,7(16):2485-92.
[93]Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F,Croce CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR 16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2002,99(24):15524-9.
[94]Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E,Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol JT-Nature cell biology,2008,10(2):202-10.
[95]Ma L, Teruya-Feldstein J,Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature JT-Nature, 2007,449(7163):682-8.
[96]Park SM, Gaur AB, Lengyel E,Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev JT-Genes & development,2008,22(7):
894-907.
[97]Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL,Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature JT-Nature,2008,451(7175):147-52.
[98]Bartel DP. MicroRNAs:target recognition and regulatory functions. Cell JT Cell,2009,136(2):215-33.
[99]99 Carleton M, Cleary MA,Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle JT-Cell cycle (Georgetown, Tex.),2007,6(17):2127-32.
[100]Ventura A, Jacks T. MicroRNAs and cancer:short RNAs go a long way. Cell JT-Cell,2009,136(4):586-91.
[101]Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M,Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2004,101(32):11755-60.
[102]Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ,Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res JT-Nucleic acids research,2005,33(20):el79.
[103]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR,Golub TR. MicroRNA expression profiles classify human cancers. Nature JT-Nature,2005,435(7043):834-8.
[104]Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B,Velculescu VE. The colorectal microRNAome. Proc Natl Acad Sci U S A JT-Proceedings of the National Academy of Sciences of the United States of America,2006,103(10):3687-92.
[105]Thompson RC, Deo M,Turner DL. Analysis of microRNA expression by in situ hybridization with RNA oligonucleotide probes. Methods JT-Methods (San Diego, Calif.),2007,43(2):153-61.
[106]Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue
T,Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene JT-Oncogene, 2006,25(17):2537-45.
[107]Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M,Hu CX. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol JT Journal of gastroenterology and hepatology,2008,23(1):87-94.
[108]Zorio E, Medina P, Rueda J, Millan JM, Arnau MA, Beneyto M, Marin F, Gimeno JR, Osca J, Salvador A, Espana F,Estelles A. Insights into the role of microRNAs in cardiac diseases:from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem JT-Cardiovascular & hematological agents in medicinal chemistry,2009,7(1):82-90.
[109]Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J,Tu L. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem JT-The Journal of biological chemistry,2009,284(43): 29596-604.
[110]Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST,Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem JT The Journal of biological chemistry,2008,283(48):33394-405.
[111]Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN,Steer CJ. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer JT-BMC cancer,2009,9:401.
[112]Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM,Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res JT-Cancer research,2008,68(15): 6162-70.
[113]Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG,
Volinia S, Croce CM, Schmittgen TD, Ghoshal K,Jacob ST. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res JT-Cancer research,2008,68(13):5049-58.
[114]Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, Terasawa K, Sato F, Tsujimoto G,Shimizu K. MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells. Nucleic Acids Res JT Nucleic acids research,2009,37(11):3821-7.
[115]Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QS, Xin M, Wang F, Appel B,Lu QR. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron JT-Neuron,2010,65(5):612-26.
[116]Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR,Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res JT-Cancer research, 2007,67(6):2456-68.
[117]L X, Z Y, Z Y, D J, W K,F D. Survival Prediction of Gastric Cancer by a Seven-microRNA Signature. Gut JT-Gut,2009.
[118]Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM,Yi XZ. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res JT-Journal of experimental & clinical cancer research:CR,2009,28:64.
[119]Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C,Lui WO. MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. J Invest Dermatol JT-The Journal of investigative dermatology,2010.
[120]Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M,Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol JT-The Journal of pathology,2008,216(4):418-27.
[121]Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz
S,Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol JT-Nature cell biology, 2009,11(12):1487-95.
[122]Tryndyak VP, Beland FA,Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer JT-International journal of cancer. Journal international du cancer, 2010,126(11):2575-83.
[123]Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA,Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res JT-Cancer research,2009,69(16):6704-12.
[124]Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA,Summerhayes IC. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol JT-Urologic oncology,2009.
[125]Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK,Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther JT Molecular cancer therapeutics,2009.
[126]Yang SZ, Zhang LD, Zhang Y, Xiong Y, Zhang YJ, Li HL, Li XW,Dong JH. HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun JT-Biochemical and biophysical research communications,2009,382(3):555-60.
[127]Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR,Futscher BW. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One JT-PloS one, 2010,5(1):e8697.
[128]Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K,Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell JT-Cell,2009,138(3):592-603.
[129]Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI,Kovalchuk
O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer JT International journal of cancer. Journal international du cancer,2010.
[130]Cochrane DR, Howe EN, Spoelstra NS,Richer JK. Loss of miR-200c:A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol JT-Journal of oncology,2010,2010:821717.
[131]Wan Q, Kuang E, Dong W, Zhou S, Xu H, Qi Y,Liu Y. Reticulon 3 mediates Bcl-2 accumulation in mitochondria in response to endoplasmic reticulum stress. Apoptosis JT-Apoptosis:an international journal on programmed cell death,2007,12(2):319-28.
[132]Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D,Lagneaux L. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood JT-Blood,2009,113(21):5237-45.
[133]Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S,Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res JT-Cancer research,2010,70(5):1916-24.
[134]Wang G, Zhang H, He H, Tong W, Wang B, Liao G, Chen Z,Du C. Up-regulation of microRNA in bladder tumor tissue is not common. Int Urol Nephrol JT-International urology and nephrology,2010,42(1):95-102.
[135]Park SY, Lee JH, Ha M, Nam JW,Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol JT-Nature structural & molecular biology,2009,16(1):23-9.
[136]Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS,Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem JT-The Journal of biological chemistry, 2009,284(9):5731-41.
[137]Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A,Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem
cells. BMC Med JT-BMC medicine,2008,6:14.
[138]Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM,Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell JT-Cancer cell,2008,13(3):272-86.
[139]Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ,Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA JT-RNA (New York, N.Y.),2008,14(1):35-42.
[140]Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR,Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res JT-Clinical cancer research:an official journal of the American Association for Cancer Research,2008,14(2):419-27.
[141]Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K,Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology JT-Hepatology (Baltimore, Md.),2009,49(4): 1098-112.
[1]Bartel DP. MicroRNAs:genomics,biogenesis,mechanism,and function. Cell, 2004,116(2):281.
[2]Zamore PD, Haley B. Ribo-gnome:the big world of small RNAs. Science, 2005,309 (5740):1519-1524.
[3]Krutzfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet,2006,38 Suppl:S14-19.
[4]McManus MT. MicroRNAs and cancer. Semin Cancer Biol,2003,13(4): 253-258.
[5]Lee RC, Feinbaum RL, Ambros V C, et al. The heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell,1993, 75(5):843-854.
[6]Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006,6(11):857.
[7]Hwang HW, Mendell JT. microRNAs in cell proliferation,cell death,and tumorigenesis. Br J Cancer,2006,94(6):776-780.
[8]Jovanovic M, Hengartner MO. miRNAs and apoptosis:RNAs to die for. Oncogene,2006,25(46):6176-6187.
[9]Lu Y, Thomson JM, Wong HY, et al. Transgenic over-expression of the microRNAmiR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol,2007,310(2):442-453.
[10]He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature,2005,316(5824):604.
[11]Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev,2006,16(1): 4-9.
[12]Esquela-Kerseher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer,2006,6(4):259-269.
[13]Cho WC. OncomiRs:the discovery and progress of microRNAs in cancers. Mol Cancer,2007,6:60.
[14]Reinhart BJ, Slack FJ, Basson M, et al. The 21 nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature,2000,403(6772): 901-906.
[15]Cummins JM, He Y, Leary RJ,et al. The colorectal microRNAome. Proc Natl Acad Sci USA,2006,103(10):3687-3692.
[16]Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature,2004,432(7014):231-235.
[17]Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science,2004,303(5654):95-98.
[18]Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA, 2004,10(2):185-191.
[19]Ouellet DL, Perron MP, Gobeil LA, et al. MicroRNAs in gene regulation:when the smallest governs it all. J Biomed Biotechnol,2006,2006(4):69616.
[20]Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature,2005, 433(7027):769-773.
[21]Brennecke J, Stark A, Russell RB, et al. Principles of microRNA target recognition. PLoS Biol,2005,3(3):e85.
[22]Xiao L, Rao JN, Zou T, et al. Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol Biol Cell,2007,18(11):4579-4590.
[23]Lai EC. Micro RNAs are complementary to 3'UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet,2002,30(4): 363-364.
[24]Kim VN. Small RNAs:classification, biogenesis, and function. Mol Cells,2005, 19(1):1-15.
[25]Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev,2006,20(5):515-524.
[26]Wu L, Fan J, Belasco JG MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A,2006,103(11):4034-4039.
[27]Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science,2005,309(5740): 1577-1581.
[28]Esquela-Kerseher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev cancer,2006,6(4):259-269.
[29]Schmittgen TD, Jiang J, Liu Q, et al. A high-through put method to monitor the expression of microRNA precursors. Nucleic Acids Res,2004,32(4):e43.
[30]Chen C, Ridzon DA, Broomer AJ, et al. Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res,2005,33(21):e183.
[31]Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human andmouse tissues. Proc Natl Acad Sci U S A,2004,101(26):9740-9744.
[32]Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A,2002,99(24):15524-15529.
[33]O'Donnell KA, Wentzel EA, Zeller KI, et al. C-Myc-regulated microRNAs modulate E2F1 expression. Nature,2005,435(7043):839-843.
[34]Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A,2006, 103(7):2257-2261.
[35]Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature,2005,435(7043):834-838.
[36]Vinther J, Hedegaard MM, Gardner PP, et al. Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res, 2006,34(16):e107.
[37]Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol,2008,141(5):672-675.
[38]Mitchell PS, Porkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A,2008, 105(30):10513-10518.
[39]Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell,2003,115 (7):787-798.
[40]Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res,2005,65(16):7065-7070.
[41]Metzler M, Wilda M, Busch K, et al. High expression of precursor microRNA-155/B IC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer,2004,39 (2):167-169.
[42]Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A,2005,102(10):3627-3632.
[43]Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun,2005, 334(4):1351-1358.
[44]Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an anti-apoptotic factor in human glioblastoma cells. Cancer Res,2005,65(14):6029-6033.
[45]Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res,2004,64(11):3753-3756.
[46]Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancermetastasis. Nature,2008,451(10):147-152.
[47]Cimmino A, Calin GA, Fabbri M, et al. MiR-15 and miR-16 induce apoptosis by targeting BCL-2. Proc Natl Acad Sci U S A,2005,102(39):13944-13949.
[48]Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A,2004,101(9):2999-3004.
[49]Motola-Kuba D, Zamora-Valdes D, Uribe M, et al. Hepatocellular carcinoma. An overview. Ann Hepatol,2006,5(1):16-24.
[50]Levrero M. Viral hepatitis and liver cancer:the case of hepatitis C. Oncogene, 2006,25(27):3834-3847.
[51]Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology,2004,40(3): 667-676.
[52]Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res,2008,14(2):419-427.
[53]Roberts LR, Gores GJ. Hepatocellular carcinoma:molecular pathways and new therapeutic targets. Semin Liver Dis,2005,25(2):212-225.
[54]Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene,2006,25(17):2537-2545.
[55]Wang Y, Lee A T, Ma J Z, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem,2008,283(19): 13205-13215.
[56]Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem,2006,99(3):671-678.
[57]Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology,2007,133(2):647-658.
[58]Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res,2007,67(13):6092-6099.
[59]Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008,27(43):5651-5661.
[60]Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology,2008,47(4): 1223-1232.
[61]Huang YS, Dai Y, Yu XF, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol,2008,23(1):87-94.
[62]Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology,2008,47(6):1955-1963.
[63]Gupta GP, Massague J. Cancermetastasis:building a framework. Cell,2006, 127(4):679-695.
[64]Wu X, Fan J, Wang X, et al. Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. Biochem Biophys Res Commun,2007, 355(4):866-871.
[65]Budhu A, Jia H L, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology,2008,47(3):897-907.
[66]Li W, Xie L, He X, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer,2008,123(7):1616-1622.
[67]Si ML, Zhu S,Wu H, et al. miR-21-mediated tumor growth. Oncogene,2007, 26(19):2799-2803.
[68]Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with'antagomirs'. Nature,2005,438(7068):685-689.
[1]GARCIA-TSAO G,SANYAL AJ,GRACE ND,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrh-osis[J]. Hepatology,2007,46(3):922-38.
[2]GARCIA-TSAO G, GROSZMANN RJ, FISHER RL,et al Portal pressure, presence of gastroesophageal varices and ariceal bleeding[J]. HEP-ATOLOGY,1985,5:419-424.
[3]ABRALDES JG, TARANTINO I, TURNES J, et al. Hmodynamic response to pharmacological treatment of portal hypertension And longte-rm prognosis of cirrhosis[J].HEPATOLOGY,2003,37:902-908.
[4]D'AMICO G, GARCIA-PAGAN JC, LUCA A, at al. HVPG reduction and prevention of variceal bleeding in cirrhosis. A systematic revie-w[J]. Gastroenterology,2006,13(5):1611-24.
[5]ALBILLOS A,BANARES R,CONZALZ M,et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis[J]. Am J Gastroenterol,2007,102(5):1116-26.
[6]D'AMICO G, PAGLIARO L, BOSCH J,et al. Pharmacological treatment of portal hypertension:an evidence-based approach[J]. Semin Liver Dis,1999, 19:475-505
[7]DE FRANCHIS R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol,2005,43:167-176.
[8]MERKEL C, MARTN R,ANGELI P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis[J].Gastroenterology,2004,127(2):476-84.
[9]GROSZMANN RJ, GARCIA-TSAO G,BOSCH J,et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J].N Engl J Med,2005, 353:2254-2261.
[10]D'AMICO G, GARCIA-TSAO G, CALES P, et al. Diagnosis of portal hypertension:how and when. In:de Franchis R.Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies[J]. Oxford, UK: Blackwell Science,2001:36-64.
[11]DIANE R. ABRACZINSKAS, RIE OOKUBO,et al.Propranolol for the Prevention of First Esophageal Variceal Hemorrhage:A Lifetime Commitment?[J].HEPATOLOGY,2001,34:1096-1102
[12]LO GH, CHEN WC, CHEN MH,et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis[J].Gastrointest Endosc,2004,59:333-338.
[13]SCHEPKE M, KLEBER G, NURNBERG D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis [J]. HEPATOLOGY,2004,40:65-72.
[14]LAY CS, TSAI YT, LEE FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis[J]. J Gastroenterol Hepatol,2006,21:413-419.
[15]ANNA V, LONGACRE, AVLIN IMAEDA,et al. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage[J].hepatology,2008,47(l):169-76.
[16]JUTABHA R, JENSEN DM, MARTIN P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices[J]. Gastroenterology,2005,128:870-81
[17]BUREAU C, PERON JM, ALRIC L, et al. "A la Carte" treatment of portal hypertension:adapting medical therapy to hemodynamic response for the prevention of bleeding [J]. HEPATOLOGY,2002,36:1361-1366.
[18]BOSCH J. A la carte or menu fixe:Improving pharmacologic therapy of portal hypertension[J].Hepatology,2002,36:1330-1332.
[19]GARCIA-PAGAN JC, VILLANUEVA C, VILA MC, et al. Mononitrato Varices Esofagicas:Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers[J]. Gastroenterology, 2001,121:908-914.
[20]BORRONI G, SALERNO F, CAZZANIGA M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites[J]. J Hepatol,2002,37(3):315-21.
[21]LUI HF, STANLEY AJ, FOREST EH, et al Primary prophylaxis of variceal hemorrhage:a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate[J].Gastroenterology,2002,123 (3): 735-44
[22]ANGELICO M,CARLI L, PIAT C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis[J]. Gastroen-terology,1993,104:1460-1465
[23]ANGELICO M,CARLI L, PIAT C, et al Effects of Isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis[J]. Gastroenterology,1997,113:1632-1639.
[24]MERKEL C, MARTN R, ENZO E, et al.Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP)[J]. lancet,1996, 348(9043):1677-81
[25]MERKEL C,MARIN R, ENZO E, et al Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis[J]. Hepatology,2000,31(2):324-9.
[26]JUAN CARLOS, GARCFA-PAG'AN, ROSA MORILLAS, et al.Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed:a double-blind RCT[J].Hepatology, 2003,37(6):1260-6.
[27]POZZI M, GRASSI G, RATTI L, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child a cirrhosis[J]. Am J Gastroenterol,2005,100(5):1110-1116
[28]BOLONDI L, PISCAGLIA F, GATTA A, et al.Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis[J]. Clin Gastroenterol Hepatol,2006,4(11):1395-402.
[29]NEVENS F, LIJNEN P, VANBILLOEN H, et al The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites[J].Hepatology,1996,23(5):1047-52
[30]SEN S, DE BK, BISWAS PK, et al.One in liver cirrhosis and propranolol-resistant portal hypertension[J].Indian J Gastroenterol,2002,21 (4):145-8
[31]ABECASIS R, KRAVETZ D, FASSIO E, et al Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients:A preliminary study[J].Hepatology,2003,37(2):359-65
[32]左文革,王春平.薛兴存食管静脉曲张首次出血前药物干预的随机对照研究[J].肝脏,2007,12(05)：342-345
[33]BANARES R, MOITINHO E,MATILLA A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. HEPATOLOGY,2002,36:1367-1373
[34]LIN HC, YANG YY, HOU MC, et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis[J].Am J Gastroenterol,2004,99:1953-1958
[35]PERELLO A, ESCORSELL A, BRU C,et al Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis [J]. HEPATOLOGY,1999,30:1393-1397.
[36]GROSZMANN RJ, WONGCHARATRAWEE S. The hepatic venous pressure gradient:Anything worth doing should be done right[J]. HEPATOLOGY, 2004,39:280-283.
[37]GARCIA-PAGAN JC, SANTOS C, BARBERA JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portalhypertension[J]. Gastroenterology,1996,111:1300-1306.
[38]MCCORMICK PA, DICK R, GRAFFEO M, et al. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patientswith cirrhosis[J]. J Hepatol,1990,11:221-225.
[39]MILLER LS, KIM JK, DAI Q, et al. Mechanics and hemodynamics of esophageal varices during peristaltic contraction[J]. Am J PhysiolGastrointest Liver Physiol,2004,287:G830-G835.
[40]OKUDA K, KONO K, OHNISHI K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly [J]. Gastroenterology,1984,86:600-610.
[41]THALHEIMER U, TRIANTOS C, SAMONAKIS D, et al. Infection, coagulation and variceal bleeding in cirrhosis. A review[J]. Gut,2005, 54:556-563
[42]PEREZ-PARAMO M, MUNOZ J,ALBILLOS A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites[J]. Hepatology,2000,31:43-48.
[43]CHOLONGITAS E,PAPATHEODORIDIS GV,MANESIS EK, et al. Spontaneos bacterial peritonitis in cirrhotic patients:is prophylactic propranolol therapy beneficial?[J] J Gastroenterol Hepatol,2006,21:581-587.